Uncategorized
For What’s Next: Preparing Today’s Lab or Tomorrow’s Discoveries
Modern biology is accelerating at an unprecedented pace, and with it comes increasing complexity. As a result, researchers are shifting toward more patient reflective models, uncovering richer phenotypes, and generating multidimensional datasets that push the limits of traditional workflows. However, become more sophisticated, operational challenges grow. Manual steps introduce variability, workflows don’t scale cleanly across teams or sites, and data pipelines struggle to keep pace with expanding volume and nuance. The result is a familiar bottleneck—ambitious science constrained by throughput, reproducibility, and the significant hands-on time required just to keep experiments moving.
This eBook brings together a curated collection of resources to help you break through those constraints. Each asset addresses the fundamental challenge of how to build workflows that are reproducible, scalable, and capable of generating confident, decision ready data. From emerging trends in 3D biology to actionable insights for implementing advanced models, the resources in this collection reflect how labs are adapting tools, methods, and data strategies to keep pace with increasingly complex science.
Discover how automation elevates upstream processes such as colony picking, clone selection, and supports specialized microbiome workflows by reducing bottlenecks and tightening reproducibility. Explore how AI powered automation helps ensure consistent performance across users and sites for both 2D and 3D model generation and expansion while reducing variability, supporting reliable organoid expansion, and returning valuablevtime to scientists by removing repetitive work. Learn how fast, quantitative plate based assays help teams quickly pinpoint meaningful biological responses, focusing deeper profiling where it will have the greatest impact. And see how high content imaging paired with AI enabled analysis reveals subtle phenotypes that traditional readouts often overlook, connecting treatment effects to underlying biology with far greater clarity.
Together, these insights reflect a unified strategy built FOR WHAT’S NEXT: integrated workflows and intelligent precision-automation that deliver reproducible results, scale seamlessly, reduce manual intervention, and support increasingly complex biology.
The post For What’s Next: Preparing Today’s Lab or Tomorrow’s Discoveries appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
How Trump is pushing psychedelics reform through the health agencies
WASHINGTON — President Trump moved on Saturday to “reverse the crisis of serious mental illness in America” by boosting access to psychedelic drugs in clinical settings. In an executive order, he directed the federal government to rush access to treatments and reevaluate their status as controlled substances.
The order directs the Food and Drug Administration to expedite some psychedelics as breakthrough drugs, as well as allowing them to be used through right-to-try legislation, which allow terminally ill patients to try experimental drugs outside of usual regulatory pathways.
Uncategorized
Optimism for Trump’s CDC pick is tempered by questions about RFK Jr.’s role
The nomination of a new leader for the Centers for Disease Control and Prevention — one who has scientific credentials and no public ties to the anti-vaccine movement — has generated sighs of relief in the public health world.
As one CDC employee, who asked not to be named, put it on Friday, among staff “the general vibe is guarded but hopeful.”
The nomination of a new leader for the Centers for Disease Control and Prevention — one who has scientific credentials and no public ties to the anti-vaccine movement — has generated sighs of relief in the public health world.
As one CDC employee, who asked not to be named, put it on Friday, among staff “the general vibe is guarded but hopeful.”
Uncategorized
RevMed’s stunning success; FDA to reclassify peptides; and more
RevMed’s stunning success; FDA to reclassify peptides; and more
Welcome back to Endpoints Weekly! Q1 earnings season is officially upon us. Max Gelman kicked off our coverage this week with a story about Johnson & Johnson’s confidence in navigating biosimilar competition … Read More
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Uncategorized9 years agoThe old and New Edition cast comes together to perform
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years agoDisney’s live-action Aladdin finally finds its stars